Cessatech (CESSA) Q4 2025 earnings summary

Executive summary

• Achieved major clinical and regulatory milestones for lead asset CT001, including completion of final pediatric study and EMA submission validation.

• Strengthened financial position with a directed share issue raising approx. DKK 14.6 million.

• Extended US partnership and completed technology transfer for CT001, supporting near-term US hospital availability.

• Leadership team reinforced with CSO appointment to Executive Management.

Financial highlights

• 2025 revenue: DKK 5,718k, mainly from upfront and milestone payments from Proveca.

• Operating loss: DKK -14,967k, improved from DKK -19,053k in 2024.

• Net loss for 2025: DKK -10,904k (2024: DKK -14,670k).

• Cash at year-end: DKK 8,591k; total assets: DKK 13,389k.

• Solvency ratio: 91%; EPS: DKK -0.60.

Outlook and guidance

• Negative cash flow expected in 2026 as development continues; first US revenue anticipated in 2026.

• Company remains dependent on capital increases or product rights sales until positive cash flow is achieved.